// App-Quantinova.ai

9528 : Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).

Researchers

Presenter

  • James M. G. Larkin

Principal Investigators

  • Grant A. McArthur

  • Antoni Ribas

  • Paolo Antonio Ascierto

  • Jorge D Gallo

  • Isabelle Anne Rooney

  • Ilsung Chang

  • Brigitte Dreno

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • Nantes University Hospital, Nantes, France

Locations

  • Italy

  • United Kingdom

  • Switzerland

  • Australia

  • United States

  • France

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Cobimetinib

  • Vemurafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01689519

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved